KR102462177B1 - Ｍｄｍ２ 억제제의 간헐적 투여 - Google Patents

Ｍｄｍ２ 억제제의 간헐적 투여 Download PDF

Info

Publication number
KR102462177B1
KR102462177B1 KR1020167035797A KR20167035797A KR102462177B1 KR 102462177 B1 KR102462177 B1 KR 102462177B1 KR 1020167035797 A KR1020167035797 A KR 1020167035797A KR 20167035797 A KR20167035797 A KR 20167035797A KR 102462177 B1 KR102462177 B1 KR 102462177B1
Authority
KR
South Korea
Prior art keywords
cancer
mdm2i
delete delete
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167035797A
Other languages
English (en)
Korean (ko)
Other versions
KR20170017932A (ko
Inventor
스테판 페레티
세바스티엔 제이
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102462177(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020227037821A priority Critical patent/KR20220151027A/ko
Publication of KR20170017932A publication Critical patent/KR20170017932A/ko
Application granted granted Critical
Publication of KR102462177B1 publication Critical patent/KR102462177B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167035797A 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여 Active KR102462177B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227037821A KR20220151027A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
US62/017,406 2014-06-26
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037821A Division KR20220151027A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여

Publications (2)

Publication Number Publication Date
KR20170017932A KR20170017932A (ko) 2017-02-15
KR102462177B1 true KR102462177B1 (ko) 2022-11-04

Family

ID=53510950

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167035797A Active KR102462177B1 (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여
KR1020247021711A Ceased KR20240110659A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여
KR1020227037821A Ceased KR20220151027A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247021711A Ceased KR20240110659A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여
KR1020227037821A Ceased KR20220151027A (ko) 2014-06-26 2015-06-25 Ｍｄｍ２ 억제제의 간헐적 투여

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR102462177B1 (enExample)
CN (2) CN106456635A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
RU2762573C2 (ru) * 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
EP3600326B1 (en) * 2017-03-31 2023-01-25 Novartis AG Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
JP7358372B2 (ja) * 2018-03-12 2023-10-10 羅欣薬業（上海）有限公司 イミダゾピロロン化合物及びその使用
US20210363254A1 (en) 2018-03-20 2021-11-25 Novartis Ag Pharmaceutical combinations
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
AU2019273850B2 (en) 2018-05-25 2024-11-14 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
CA3123356A1 (en) 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
EP4031139A1 (en) 2019-09-16 2022-07-27 Novartis AG Use of an mdm2 inhibitor for the treatment of myelofibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EA019566B1 (ru) 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
UA108746C2 (xx) * 2009-12-22 2015-06-10 Заміщені ізохінолінони та хіназолінони
PL2361667T3 (pl) 2010-02-25 2015-07-31 General Electric Technology Gmbh Płuczka wodna i sposób oczyszczania gazu procesowego
MX2013005238A (es) * 2010-11-12 2013-09-02 Univ Michigan Antagonistas de mdm2 de espiro-oxindol.
CN103261229A (zh) * 2010-12-16 2013-08-21 罗切格利卡特公司 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
EP2741824B1 (en) 2011-08-11 2017-05-03 Estetra S.P.R.L. Use of estetrol as emergency contraceptive
EP2793890B1 (en) 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
PT2880447T (pt) 2012-07-31 2019-08-02 Novartis Ag Marcadores associados à sensibilidade a inibidores de minuto duplo humano 2 (mdm2)
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2015082384A1 (en) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
AU2014372167A1 (en) 2013-12-23 2016-06-09 Novartis Ag Pharmaceutical combinations
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
AU2016215035A1 (en) 2015-02-06 2017-09-28 Buck Institute For Research On Aging Compounds and uses in treatment of senescence-associated conditions
HK1251165A1 (en) 2015-04-13 2019-01-25 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
TWI804010B (zh) 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
ES2962460T3 (es) 2015-08-28 2024-03-19 Novartis Ag Inhibidores de mdm2 y combinaciones de estos
RU2762573C2 (ru) 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
US20190337952A1 (en) 2016-11-22 2019-11-07 Novartis Ag Chemical Process for Preparing Imidazopyrrolidinone Derivatives and Intermediates Thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EP3600326B1 (en) 2017-03-31 2023-01-25 Novartis AG Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11406627B2 (en) 2017-10-12 2022-08-09 Novartis Ag Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
US20210363254A1 (en) 2018-03-20 2021-11-25 Novartis Ag Pharmaceutical combinations
IL282485B2 (en) 2018-10-30 2025-09-01 Dana Farber Cancer Inst Inc Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53
CA3123356A1 (en) 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
AU2020251019B2 (en) 2019-04-04 2022-01-27 Novartis Ag Siremadlin succinate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Giampaolo Tortora al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Caner Therapy, v.88(5), pp.8*
J.-J. Qin et al. Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. Current Medicinal Chemistry, v.19(33), pp.5705-5725 (2012.11.1.)*

Also Published As

Publication number Publication date
TW201613576A (en) 2016-04-16
JP2017519019A (ja) 2017-07-13
JP6728072B2 (ja) 2020-07-22
RU2017102319A (ru) 2018-07-26
US20180110779A1 (en) 2018-04-26
WO2015198266A1 (en) 2015-12-30
KR20240110659A (ko) 2024-07-15
AU2015278765B2 (en) 2018-08-16
US20240261284A1 (en) 2024-08-08
MX2016017075A (es) 2017-05-03
IL249138B (en) 2020-09-30
RU2695228C2 (ru) 2019-07-22
BR112016029750A2 (pt) 2017-08-22
US11419870B2 (en) 2022-08-23
US20170196866A1 (en) 2017-07-13
EP3160463B1 (en) 2020-10-21
KR20220151027A (ko) 2022-11-11
TN2016000522A1 (en) 2018-04-04
CN115569197A (zh) 2023-01-06
EP3160463A1 (en) 2017-05-03
CA2953079A1 (en) 2015-12-30
CL2016003295A1 (es) 2017-07-28
ES2856210T3 (es) 2021-09-27
AU2015278765A1 (en) 2017-01-19
IL249138A0 (en) 2017-01-31
US20230092181A1 (en) 2023-03-23
PH12016502556A1 (en) 2017-04-17
US20210000824A1 (en) 2021-01-07
US20220233530A9 (en) 2022-07-28
CN106456635A (zh) 2017-02-22
CA2953079C (en) 2023-05-02
KR20170017932A (ko) 2017-02-15
RU2017102319A3 (enExample) 2019-02-12
SG11201609853VA (en) 2017-01-27
US20190209561A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
US20240261284A1 (en) Intermittent dosing of mdm2 inhibitor
JP6890659B2 (ja) ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
KR102845148B1 (ko) Her2 양성 암의 치료
JP2023533485A (ja) 重症型の肺高血圧症の治療方法
JP2015514796A (ja) ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体
KR20240164794A (ko) 암 치료를 위한 병용 요법
US20230038138A1 (en) Combination therapy for treating cancer
US11980628B2 (en) Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (AhR) and SRC
WO2021175432A1 (en) Method for administration of an anti cancer agent
US9545396B2 (en) Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
US20240293425A1 (en) Bzd-1 as a chemosensitizer of cancer
US9750728B2 (en) Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
HK40064613A (en) Methods for treating cancer
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200624

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220311

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220728

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221028

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221028

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221031

End annual number: 3

Start annual number: 1

PG1601 Publication of registration